Skip Navigation


Annals of Oncology Advance Access originally published online on April 25, 2005
Annals of Oncology 2005 16(6):928-933; doi:10.1093/annonc/mdi182
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
16/6/928    most recent
mdi182v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (19)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Hara, S.
Right arrow Articles by Murai, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hara, S.
Right arrow Articles by Murai, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society for Medical Oncology

Akt activation in renal cell carcinoma: contribution of a decreased PTEN expression and the induction of apoptosis by an Akt inhibitor

S. Hara, M. Oya*, R. Mizuno, A. Horiguchi, K. Marumo and M. Murai

Department of Urology, Keio University School of Medicine, Tokyo, Japan

* Correspondence to: Dr M. Oya, Department of Urology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan. Tel: +81-3-5363-3825; Fax: +81-3-3225-1985; Email: moto-oya{at}sc.itc.keio.ac.jp

Background:: Akt has been implicated in the oncogenesis of human malignant tumors, because Akt regulates many key effector molecules involved in cell survival. PTEN (phosphatase and tensin homolog deleted on chromosome 10) negatively regulates Akt activation.

Materials and methods:: The expression of phosphorylated Akt (p-Akt), total Akt and PTEN was analyzed by Western blotting in 45 renal cell carcinoma (RCC) patients. The Bad and phosphorylated Bad (p-Bad) statuses were analyzed in 20 RCC patients. A phosphatidylinositol ether analog was used as an Akt inhibitor to treat four RCC cell lines, namely Caki-1, KU19-20, SW839 and Caki-2.

Results:: The PTEN expression in RCC was observed to decrease and p-Akt expression to increase significantly in comparison with that in the corresponding normal kidney tissue. The PTEN expression inversely correlated with the p-Akt expression. These alterations were specific for clear cell type RCC, but not for papillary or chromophobe type RCC. Alterations in Bad phosphorylation were also specifically observed in clear cell type. The Akt inhibitor induced apoptosis in KU19-20 and Caki-2 cells with a high Akt activity.

Conclusions:: A decreased expression of PTEN may be an underlying mechanism for Akt activation. An Akt inhibitor may be a therapeutic option for a subset of RCC with an elevated Akt activity.

Key words: Akt, Bad, PTEN, renal cell carcinoma


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Therapeutic Advances in Medical OncologyHome page
T. B. Dorff, A. Goldkorn, and D. I. Quinn
Review: Targeted therapy in renal cancer
Therapeutic Advances in Medical Oncology, November 1, 2009; 1(3): 183 - 205.
[Abstract] [PDF]

Home page
 Clin. Cancer Res.Home page
N. Tsukamoto, S. Okada, Y. Onami, Y. Sasaki, K. Umezawa, and Y. Kawakami
Impairment of Plasmacytoid Dendritic Cells for IFN Production by the Ligand for Immunoglobulin-Like Transcript 7 Expressed on Human Cancer Cells
Clin. Cancer Res., September 15, 2009; 15(18): 5733 - 5743.
[Abstract] [Full Text] [PDF]

Home page
 Therapeutic Advances in Medical OncologyHome page
J. M.G. Larkin, E. L.S. Kipps, C. J. Powell, and C. Swanton
Review: Systemic therapy for advanced renal cell carcinoma
Therapeutic Advances in Medical Oncology, July 1, 2009; 1(1): 15 - 27.
[Abstract] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Kim, E. Jonasch, A. Alexander, J. D. Short, S. Cai, S. Wen, D. Tsavachidou, P. Tamboli, B. A. Czerniak, K. A. Do, et al.
Cytoplasmic Sequestration of p27 via AKT Phosphorylation in Renal Cell Carcinoma
Clin. Cancer Res., January 1, 2009; 15(1): 81 - 90.
[Abstract] [Full Text] [PDF]

Home page
 GlycobiologyHome page
H.-J. Choi, T.-W. Chung, S.-J. Kim, S.-Y. Cho, Y.-S. Lee, Y.-C. Lee, J.-H. Ko, and C.-H. Kim
The AP-2{alpha} transcription factor is required for the ganglioside GM3-stimulated transcriptional regulation of a PTEN gene
Glycobiology, May 1, 2008; 18(5): 395 - 407.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J.-I Chao, W.-C. Su, and H.-F. Liu
Baicalein induces cancer cell death and proliferation retardation by the inhibition of CDC2 kinase and survivin associated with opposite role of p38 mitogen-activated protein kinase and AKT
Mol. Cancer Ther., November 1, 2007; 6(11): 3039 - 3048.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. Cho, S. Signoretti, M. Regan, J. W. Mier, and M. B. Atkins
The Role of Mammalian Target of Rapamycin Inhibitors in the Treatment of Advanced Renal Cancer
Clin. Cancer Res., January 15, 2007; 13(2): 758s - 763s.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.